When was Endonovo Therapeutics founded?

Endonovo Therapeutics was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is Endonovo Therapeutics located?

Endonovo Therapeutics is headquartered in Los Angeles, United States.

Who is the current CEO of Endonovo Therapeutics?

Alan Collier of Endonovo Therapeutics.

How many employees does Endonovo Therapeutics have?

As of May 31, 2026, the latest employee count at Endonovo Therapeutics is 5.

Is Endonovo Therapeutics a funded company?

Endonovo Therapeutics is a funded company, having raised an undisclosed amount across 9 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 11, 2014.

When was the latest funding round of Endonovo Therapeutics?

Endonovo Therapeutics' latest funding was a $***** Post IPO round on May 26, 2020, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.15B in funding in 2026 to date.

What is the annual revenue of Endonovo Therapeutics?

Annual revenue of Endonovo Therapeutics is less than $1M as on Dec 31, 2022

Where does Endonovo Therapeutics rank among its competitors?

Endonovo Therapeutics ranks 12th amongst 109 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Xeltis, which secured $43.6M in Dec, 2025.

Who are the top competitors of Endonovo Therapeutics?

Endonovo Therapeutics' top competitors include Precision Neuroscience, Blackrock Neurotech and Xeltis. Among them, Xeltis secured the most recent funding round in December, 2025.

Endonovo Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Endonovo Therapeutics is a public company based in Los Angeles (United States), founded in 2011. It operates as a Bioelectronic devices and therapies for regenerative medicine. Endonovo Therapeutics has raised an undisclosed amount in funding. The company has 109 active competitors, including 27 funded and 12 that have exited. Its top competitors include companies like Precision Neuroscience, Blackrock Neurotech and Xeltis.

Company Details

Bioelectronic devices and therapies for regenerative medicine. It offers a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death, and the promotion of regeneration. It also has a Cytotronics platform which provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.

Website: endonovo.com
Social
Email ID: *****@endonovo.com

Key Metrics

Founded Year

2011

Location

Los Angeles, United States

Stage

Public

Latest Funding Round

Post IPO, May 26, 2020, $*****

Investors

Azure Capital Partners & 3 more

Ranked

12^th among 109 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2022

Employee Count

5 as on May 31, 2026

Similar Companies

Precision Neuroscience & 126 more

Exit Details

Public

View Endonovo Therapeutics' full profile

Endonovo Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ENDONOVO THERAPEUTICS, INC. CIN: 1528172 , United States, Active	May 25, 2011	$0 - $1M (As on Dec 31, 2022)	-	-

Endonovo Therapeutics got listed on Nov 15, 2012.

Click here to take a look at Endonovo Therapeutics's IPO in detail

Endonovo Therapeutics has raised funding over 9 rounds. Its first funding round was on Aug 11, 2014. Its latest funding round was a Post IPO round on May 26, 2020 for $*****. 1 investor participated in its latest round. Endonovo Therapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Endonovo Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 26, 2020	2558392	Post IPO	3069039	1623618	3726021	9346292
Nov 22, 2019	6037973	Post IPO	5712201	5141866	9950709	8732697
Dec 29, 2017	2105290	Post IPO	5996505	1100442	6803774	1327576

Access funding benchmarks and valuations. Sign up today!

View details of Endonovo Therapeutics's funding rounds and investors

Endonovo Therapeutics' employee count trend

Endonovo Therapeutics has 5 employees as of May 26. Here is Endonovo Therapeutics's employee count trend over the years:

Employee count trend for Endonovo Therapeutics

Uncover Endonovo Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Endonovo Therapeutics include Precision Neuroscience, Blackrock Neurotech and Xeltis. Here is the list of Top 10 competitors of Endonovo Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Precision Neuroscience 2021, New York City (United States), Series C	Developed of brain-computer interface tool for medical treatment and drug development	$183M	Steadview, B Capital & 10 others	65/100
2nd	Blackrock Neurotech 2008, Salt Lake City (United States), Acquired	Developer of medical devices for neurological therapies	$22.4M	re.Mind Capital, Cavendish Privateers & 12 others	62/100
3rd	Xeltis 2006, Zurich (Switzerland), Series D	Developer of bioabsorbable synthetic heart valves and vascular grafts	$176M	Life Sciences Partners, Kurma Partners & 13 others	59/100
4th	Occlutech 2003, Schaffhausen (Switzerland), Series C	Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure	$70.8M	Fjarde AP-fonden, Carnegie & 5 others	56/100
5th	Nexstim 2000, Helsinki (Finland), Public	Provider of noninvasive brain stimulation for rehabilitating stroke patients	$29.7M	Lundbeck Foundation, Kreos Capital & 8 others	52/100
6th	g.tec 1999, Schiedlberg (Austria), Funding Raised	Provider of high-performance brain-computer interfaces and neurotechnologies for invasive and non-invasive recordings	-	EIC Fund, Europa	51/100
7th	Helius Medical 2014, Newtown Square (United States), Public	Developer of neurological rehabilitation medical devices	$391K	Pantera Capital, Summer Capital Management Company ... & 14 others	51/100
8th	BIONIK 2010, Toronto (Canada), Public	Provider of assistive and rehabilitation hardware and software solutions	-	Ginger Capital, MBX Capital & 3 others	48/100
9th	PECA Labs 2011, Pittsburgh (United States), Series B	Developer of pediatric cardiac surgical devices	$22.6M	BlueTree Allied Angels, Warren Point Capital ... & 5 others	48/100
10th	Synergia Medical 2013, Mont Saint Guibert (Belgium), Series B	Developer of an active implantable neurostimulator and contact-less patient monitoring system	$14.2M	Newton Biocapital, SFPI & 8 others	47/100
12th	Endonovo Therapeutics 2011, Los Angeles (United States), Public	Bioelectronic devices and therapies for regenerative medicine	-	Azure Capital Partners, Cavalry Fund & 2 others	46/100